{"id":508678,"date":"2021-07-01T07:03:17","date_gmt":"2021-07-01T11:03:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\/"},"modified":"2021-07-01T07:03:17","modified_gmt":"2021-07-01T11:03:17","slug":"pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\/","title":{"rendered":"Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">ZUG, Switzerland, July  01, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wq-vEGZHPZh2OrMjQKcLeRpTIXcfolUeI-61yigI1QYGMzmVre2V--8-GT1nNG-ViZ91pWWo61OwbEfHjbcWUQ==\" rel=\"nofollow noopener\" target=\"_blank\">Pharvaris<\/a> (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that the company will present clinical data for oral PHA121, a novel and potent bradykinin 2 receptor antagonist for treatment of hereditary angioedema, as an e-Poster at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021, to be held virtually July 10-16, 2021.<\/p>\n<p>The presentation details are as follows:<\/p>\n<p>\n        <strong>Title:<\/strong>\u00a0Multiple dose administration of PHA-022121, an orally available, bradykinin B2 receptor antagonist is well tolerated and shows a favorable pharmacokinetic profile for prophylactic treatment of HAE<br \/><strong>Poster Number:\u00a0<\/strong>602<br \/><strong>Poster Presenter:\u00a0<\/strong>Kees Groen, Ph.D.<\/p>\n<p>The abstract will be published on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QWsMtJChdIbh_7B-cv1VhtXSdMsjRwMjzYYFbemGWfT9zlxBUfhTozxv5SrT3GGTF12GJwZkrCzQkNZ1EyZFYg==\" rel=\"nofollow noopener\" target=\"_blank\">EAACI website<\/a> on Saturday, July 10. The virtual poster presentation will be on the EAACI website from July 10-16, 2021, and will be also accessible through the Investors page on the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2kmsvnIT50VlYhbbEJAImQUKdcpLu2rVLLcIUXKz-DODktWn9qsCyslPqdB8o077yXYU3xRomHaNhBcqrcH_3g==\" rel=\"nofollow noopener\" target=\"_blank\">www.pharvaris.com<\/a>.<\/p>\n<p>\n        <strong>About Pharvaris<\/strong><br \/>\n        <br \/>Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The Company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IaxmR6tyKoFGsnSZOp5DS3hfJkNK7tnXnkAcPts9erecscwqz3J5wJPzLsoqCRZs-XQsT1JtdVIKu6Aa-3cWdQcJc_9fVHWGfAUbyXQCKow=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/pharvaris.com\/<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains certain forward-looking statements that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements containing the words \u201cbelieve,\u201d \u201canticipate,\u201d \u201cexpect,\u201d \u201cestimate,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cwill,\u201d \u201cintend\u201d and similar expressions. These forward-looking statements are based on management\u2019s current expectations, are neither promises nor guarantees, and involve known and unknown risks, uncertainties and other important factors that may cause Pharvaris\u2019 actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements. Such risks include but are not limited to the following: the expected timing, progress, or success of our clinical development programs, especially for PHVS416 and PHVS719, which are in early-stage clinical trials; risks associated with the COVID-19 pandemic, which may adversely impact our business, preclinical studies, and clinical trials; the timing of regulatory approvals; the value of our ordinary shares; the timing, costs and other limitations involved in obtaining regulatory approval for our product candidates PHVS416 and PHVS719, or any other product candidate that we may develop in the future; our ability to establish commercial capabilities or enter into agreements with third parties to market, sell, and distribute our product candidates; our ability to compete in the pharmaceutical industry and with competitive generic products; our ability to market, commercialize and achieve market acceptance for our product candidates; our ability to raise capital when needed and on acceptable terms; regulatory developments in the United States, the European Union and other jurisdictions; our ability to protect our intellectual property and know-how and operate our business without infringing the intellectual property rights or regulatory exclusivity of others;\u00a0 our ability to manage negative consequences from changes in applicable laws and regulations, including tax laws, our ability to successfully remediate the material weakness in our internal control over financial reporting and to maintain an effective system of internal control over financial reporting; and the other factors described under the heading \u201cRisk Factors\u201d in our registration statement on Form 20-F and other periodic filings with the Securities and Exchange Commission.<\/p>\n<p>These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management\u2019s estimates as of the date of this press release. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. While Pharvaris may elect to update such forward-looking statements at some point in the future, Pharvaris disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Pharvaris\u2019 views as of any date subsequent to the date of this press release.<\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Sarah McCabe<br \/>Stern Investor Relations, Inc.<br \/>+1-212-362-1200<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KqxT-zIC0k9TOn6OXZMJM6uNor-cChdVwjPXQ9VfGW4xxeyj6nwrtPO6zpF50zqPJfb2f9TkgQaw7KMh3aiteT7GzD4qLgluDC59lKhT35M=\" rel=\"nofollow noopener\" target=\"_blank\">sarah.mccabe@sternir.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Maggie Beller<br \/>Russo Partners, LLC<br \/>+1-646-942-5631<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=D6LHIqlhuSeVThRc3_DumoaDkcmDNDcNNlsQng8vfEsAZ87FFKLtWr59uNE9UryXEDc5OAGFB82cH9aBdch7FsaDC35uML65-LAQGKOE0Tv86MIN9xbQPQXue1qvQDym_4D5NWTvPwrUsZsCxnALqQ==\" rel=\"nofollow noopener\" target=\"_blank\">maggie.beller@russopartnersllc.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzYxMCM0Mjc4MDY2IzIyMDU5NDc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/5c3f1aa8-8333-47e8-8067-a69846a94bef\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ZUG, Switzerland, July 01, 2021 (GLOBE NEWSWIRE) &#8212; Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that the company will present clinical data for oral PHA121, a novel and potent bradykinin 2 receptor antagonist for treatment of hereditary angioedema, as an e-Poster at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021, to be held virtually July 10-16, 2021. The presentation details are as follows: Title:\u00a0Multiple dose administration of PHA-022121, an orally available, bradykinin B2 receptor antagonist is well tolerated and shows a favorable pharmacokinetic profile for prophylactic treatment of HAEPoster Number:\u00a0602Poster Presenter:\u00a0Kees Groen, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-508678","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ZUG, Switzerland, July 01, 2021 (GLOBE NEWSWIRE) &#8212; Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that the company will present clinical data for oral PHA121, a novel and potent bradykinin 2 receptor antagonist for treatment of hereditary angioedema, as an e-Poster at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021, to be held virtually July 10-16, 2021. The presentation details are as follows: Title:\u00a0Multiple dose administration of PHA-022121, an orally available, bradykinin B2 receptor antagonist is well tolerated and shows a favorable pharmacokinetic profile for prophylactic treatment of HAEPoster Number:\u00a0602Poster Presenter:\u00a0Kees Groen, &hellip; Continue reading &quot;Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-01T11:03:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzYxMCM0Mjc4MDY2IzIyMDU5NDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021\",\"datePublished\":\"2021-07-01T11:03:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\\\/\"},\"wordCount\":756,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MzYxMCM0Mjc4MDY2IzIyMDU5NDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\\\/\",\"name\":\"Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MzYxMCM0Mjc4MDY2IzIyMDU5NDc=\",\"datePublished\":\"2021-07-01T11:03:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MzYxMCM0Mjc4MDY2IzIyMDU5NDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MzYxMCM0Mjc4MDY2IzIyMDU5NDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\/","og_locale":"en_US","og_type":"article","og_title":"Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021 - Market Newsdesk","og_description":"ZUG, Switzerland, July 01, 2021 (GLOBE NEWSWIRE) &#8212; Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that the company will present clinical data for oral PHA121, a novel and potent bradykinin 2 receptor antagonist for treatment of hereditary angioedema, as an e-Poster at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021, to be held virtually July 10-16, 2021. The presentation details are as follows: Title:\u00a0Multiple dose administration of PHA-022121, an orally available, bradykinin B2 receptor antagonist is well tolerated and shows a favorable pharmacokinetic profile for prophylactic treatment of HAEPoster Number:\u00a0602Poster Presenter:\u00a0Kees Groen, &hellip; Continue reading \"Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-01T11:03:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzYxMCM0Mjc4MDY2IzIyMDU5NDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021","datePublished":"2021-07-01T11:03:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\/"},"wordCount":756,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzYxMCM0Mjc4MDY2IzIyMDU5NDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\/","name":"Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzYxMCM0Mjc4MDY2IzIyMDU5NDc=","datePublished":"2021-07-01T11:03:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzYxMCM0Mjc4MDY2IzIyMDU5NDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MzYxMCM0Mjc4MDY2IzIyMDU5NDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-pha121-clinical-data-for-oral-treatment-of-hereditary-angioedema-at-the-eaaci-annual-congress-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/508678","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=508678"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/508678\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=508678"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=508678"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=508678"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}